Praecis submits NDA for abarelix

PRCS submitted an NDA to the FDA for abarelix depot, a luteinizing hormone releasing hormone (LHRH)/gonadotropin releasing hormone (GnRH) antagonist to treat prostate cancer. PRCS is developing abarel...